June 14, 2023 – Arlington, VA – Digital Therapeutics Alliance (DTA) is announcing the launch of the Policymaker & Payor DTx Evaluation Toolkit, a comprehensive set of resources to enable global healthcare and digital technology leaders to broaden the understanding, adoption, and integration of clinically evaluated digital therapeutics (DTx) into healthcare.
According to ISO, digital therapeutics “generate and deliver software-based medical interventions to patients to treat or alleviate a disease or disorder”. DTx products additionally provide clinicians and payors with robust opportunities to enhance clinical and health economic outcomes for patients and populations.
As part of its core mission, DTA continues to convene healthcare decision makers, end users, and industry leaders to develop a strong foundation for how patients and caregivers access and utilize digital therapeutics. This Toolkit originated through the work of the DTx Policy Coalition, which launched in June 2022, and provides clarity for healthcare decision makers responsible for evaluating and implementing DTx in real-world settings.
Components included in this Toolkit include:
In an increasingly fragmented landscape of differing product requirements and expectations within and across national jurisdictions, this Toolkit represents a first step toward enabling policymakers, payors, and manufacturers to harmonize baseline requirements and scale therapies across populations.
To that end, the Toolkit is equipped with an explanation of the benefits and challenges associated with developing and implementing DTx in clinical care, and provides education on the evaluation processes and metrics for assessing clinical benefits, risks, and patient preferences.
Through advocacy, education, and cross-industry collaboration, the Policymaker & Payor DTx Evaluation Toolkit will provide greater insight on the development and integration of DTx into healthcare, in an effort to ultimately improve patient outcomes and benefit global healthcare.
“Digital therapeutics will undoubtedly become a critical part of patient care. With the appropriate frameworks and pathways, this is the first treatment modality that can equitably scale across global healthcare settings to deliver personalized, high quality, impactful healthcare,” said Megan Coder, Chief Policy Officer of DTA. “The Policymaker & Payor DTx Evaluation Toolkit offers decision makers a full spectrum approach to understanding the complexities of DTx value assessment, legal and regulatory guidelines, and implementation, in addition to optimizing the impact of DTx therapies on patient care.”
These tools are free and open access, available to all: DTx Evaluation Toolkit – Digital Therapeutics Alliance.
About DTA
As the leading global authority on the evolution of digital health technology, Digital Therapeutics Alliance (DTA) is a 501(c)(6) non-profit trade association of industry leaders and stakeholders dedicated to the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors to improve clinical and health economic outcomes. As the leading international organization on digital therapeutic thought leadership and education, DTA provides the digital health ecosystem with the necessary tools to define, evaluate, and utilize DTx products.
Unlock the Future of Healthcare: Digital Therapeutics Alliance Inaugural Summit to Empower DTx Industry Leaders and Policymakers
Join the DTA Community June 7-9 for Three Days of Insight, Collaboration, and Innovation to Advance Digital Health Access and Equity for All.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Arlington, VA —Digital Therapeutics Alliance (DTA) is proud to announce its Inaugural Summit, to be held June 7-9, 2023 at the Washington D.C. Marriott at Metro Center. The 3-day Summit programming will be facilitated by leaders from all facets of the digital therapeutics (DTx) ecosystem, including policymakers, manufacturers, payors, and other experts to guide innovation and equity in healthcare. The Summit programming will be led by DTA CEO, Andy Molnar, and will feature lively panel discussions and interactive workshop sessions that cover the advancement of DTx, healthcare policy impacts, reimbursement and regulatory pathways, clinical evidence requirements, and patient access optimization.
In addition to the Summit, DTA members and staff will also gather on Capitol Hill June 6-7, to meet with congressional members and staff to advocate for the Access to Prescription Digital Therapeutics Act (S. 723 and H.R. 1458). This bill seeks to create a new benefit category for digital therapeutics and ensure permanent coverage and reimbursement of DTx products by Medicare and Medicaid. Ensuring access to these clinically validated therapeutics for Medicare and Medicaid patients, and other high-risk, rural, and marginalized communities.
DTA’s vision is to bridge the gap between the DTx industry and the healthcare system by providing a platform for dialogue and collaboration between different stakeholders in the DTx space. With this Summit, DTA aspires to accelerate the adoption of digital therapeutics and ensure equitable access to healthcare for all.
The 2023 DTA Summit agenda will feature:
On Friday, June 9th, the DTA Summit’s final panel will bring together senior regulatory leaders from the U.S. Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS),The Office of the National Coordinator for Health Information Technology (ONC), The Substance Abuse and Mental Health Services Administration (SAMHSA),Agency for Healthcare Research and Quality (AHRQ), and National Institutes of Health (NIH) to provide insights on their own approaches to digital therapeutics. These agencies play a critical role in the development, classification, assessment, and distribution of digital therapeutics to patients.
DTA will host a Press Conference immediately following the Summit’s final panel. The announcements will be a defining moment in digital health worldwide, involving new standards, efforts, and publications that will:
DTA Board Member and Head of WELT USA, Danny Jooyoung Kim, PharmD shares, “The DTA Summit provides an excellent platform to connect with like-minded individuals and organizations and to stay up to date on the latest trends and advancements in this rapidly evolving field. We are excited to bring about a future where digital therapeutics become a vital component of patient care worldwide.”
DTA is committed to transforming global healthcare through the advancement of DTx, and the Inaugural Summit marks a significant milestone in that journey. DTA invites industry leaders and stakeholders to participate in this important event, helping shape the future of healthcare.
###
Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org or follow us on LinkedIn.
2023 Digital Therapeutics Alliance Inaugural Summit: DTx Industry Leaders Gather to Transform Global Healthcare
Held at the Washington D.C. Marriott at Metro Center June 7 – 9, 2023.
The 3-day Summit programming will be facilitated by leaders from all facets of the DTx industry, including policymakers, manufacturers, payors, and other experts to guide innovation and equity in healthcare.
The Digital Therapeutics Alliance (DTA) is hosting its Inaugural Summit on June 7-9, 2023 at the Washington Marriott at Metro Center. Leaders from all facets of the digital therapeutics (DTx) ecosystem, including policymakers, clinicians, and payors, will join DTA members to discuss the challenges and opportunities of DTx integration into the healthcare system and identify optimized policy, reimbursement, and regulatory pathways to accelerate adoption.
The 3-day Summit programming will be facilitated by Andy Molnar, Chief Executive Officer of DTA, and feature keynote presentations, panel discussions, and interactive sessions that cover the advancement of DTx, the impact of healthcare policy, reimbursement and regulatory pathways, clinical evidence requirements, and patient access optimization.
DTA’s Chief Executive Officer, Andy Molnar states: “We are here to transform healthcare and deliver a new category of medicine to patients to improve their lives. The 2023 DTA Inaugural Summit brings together the leaders in healthcare innovation that are making these monumental changes. We are building viable frameworks with partners from Capitol Hill, the investment ecosystem, clinicians, health plans, patients, and caregivers.”
DTx products use evidence-based, clinically evaluated technologies to optimize clinical and health economic outcomes, deliver high quality therapies to underserved populations, and transform how patients understand, manage, and engage in their healthcare.
Leading into the Summit, US-focused DTA members and staff will convene in Washington D.C. to meet with congressional members and other influential parties to advocate for the Access to Prescription Digital Therapeutics Act (S. 723 and H.R. 1458). This bill seeks to create a new benefit category for digital therapeutics and ensure permanent coverage and reimbursement of DTx products by Medicare and Medicaid.
Everett Crosland, DTA board member and Chief Commercial Officer for Cognito Therapeutics, commented, “Given the rapidly evolving reimbursement environment, DTA’s 2023 Inaugural Summit offers the DTx industry an unprecedented opportunity to engage and advocate on the issues that matter most to our companies, patients, providers, and payor partners. I’m excited to speak on emerging frameworks that are shaping our future.”
Learn more about: 2023 DTA Inaugural Summit event details and registration.
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org or follow us on LinkedIn.
Media Contact:
Autumn Brennan
Digital Therapeutics Alliance
abrennan@dtxalliance.org